Key Highlights

  • Alnylam Pharmaceuticals traded at US$224.41, against a consensus target of US$384.
  • The median target of US$369 implies roughly +64.4% upside from the current price.
  • Targets span US$256 to US$549, framing the range of analyst opinion.
  • The consensus implies +71.1% upside, reflecting the balance of current analyst views.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a constituent of the Nasdaq-100, traded at US$224.41 as of 8 October 2026, against an analyst consensus price target of US$384, an implied upside of approximately +71.1%.

What Is the Latest Analyst Price Target?

The consensus (average) price target is US$384.00, while the median target is US$369.00. The median implies 64.4% upside from the current price, compared with 71.1% upside for the average. The highest published target is US$549.00, which would represent 144.6% above the current share price, and the lowest is US$256.00, or 14.1% above it.

The gap between the highest and lowest targets amounts to roughly 131% of the current share price, a wide range that points to genuine disagreement about the outlook. The shares trade on a trailing price-to-earnings ratio of about 37.8.

What Are Analysts Saying?

Individual broker upgrades, downgrades and target changes for Alnylam Pharmaceuticals, Inc. could not be independently verified in this research run. What the aggregate data does show is the distribution of targets: the average sits 71.1% above the current price, and the lowest target is above the share price while the highest is above it.

What Could Help the Stock Reach the Price Target?

Broader uptake of its transthyretin amyloidosis therapy among patients and physicians could widen the commercial base, particularly if diagnosis rates continue to improve and treatment is started earlier in the disease course. Pipeline programmes targeting larger cardiometabolic indications may open sizeable new markets if clinical data prove supportive, which could change how investors view the long-term Revenue potential of the platform. Operating Leverage could improve as product revenue scales against a relatively fixed research and commercial cost base, which may help the company move toward more consistent profitability over time.

What Could Prevent the Stock Reaching the Target?

Valuation may already reflect optimistic assumptions about future adoption, so any slower launch trajectory or disappointing trial readout could weigh on how the shares are perceived against analyst targets. Competition from other genetic medicines and from conventional treatments in its core indications could pressure pricing and market share, particularly as rival approaches mature and new entrants seek the same patients. Drug pricing scrutiny, reimbursement negotiations and clinical or regulatory setbacks are ongoing risks for a company dependent on a small number of key products and a research-intensive pipeline.

What Should Investors Watch Next?

The next quarterly results and any updated company guidance should show how the key marketed products are progressing and whether the pace of patient additions is consistent with expectations. Clinical trial updates and regulatory interactions for late-stage pipeline candidates may be an important catalyst, especially for programmes aimed at larger patient populations. Management commentary on spending discipline, Partnership income and the path toward sustained profitability could influence how investors weigh the company's Investment plans. Any of these could prompt analysts to revise their targets.

Why the Numbers on Alnylam Pharmaceuticals Diverge

Alnylam Pharmaceuticals (ALNY) was priced at US$224.41 against a consensus target of US$384, an implied upside of approximately +71.1%. The median target of US$369 and the range of US$256 to US$549 frame the debate among analysts.